Plurai, founded by former Nexar staffers to use synthetic data and digital twins of corporate IT environments to assess AI agents, raised a $13M seed (Tim Fernholz/TechCrunch)
The company focuses on assessing AI agents by deploying synthetic data and digital twins that mirror corporate IT environments. Organizations can utilize these simulated models of their technical infrastructure to evaluate automated agent performance safely. This approach helps companies scrutinize automated tools, and the team will use its newly secured capital to advance this testing technology.
Key points
Organizations can safely evaluate automated AI agents within simulated models of their in…: Organizations can safely evaluate automated AI agents within simulated models of their infrastructure.
The startup secured significant early-stage funding to advance its specialized artificial…: The startup secured significant early-stage funding to advance its specialized artificial intelligence assessment platform.
Nexar veterans are applying computer vision and technology experience to solve enterprise…: Nexar veterans are applying computer vision and technology experience to solve enterprise AI evaluation challenges.
Sources checked by our analysis pipeline: 1
April Roach / CNBC: |
New York Times: |
Desmond Shum: |
New York Times: |
New York Times: |
Owen Walker / Financial Times: |
Vlad Savov / Bloomberg: |
Bailey Lipschultz / Bloomberg: |
@firesidealpha: |
Luke Plunkett / Aftermath: |
Eduardo Baptista / Reuters: |
Bloomberg: |
Marcus Mendes / 9to5Mac: |
Berber Jin / Wall Street Journal: |
Richard Adams / The Guardian: |
Jake Roach / Tom's Hardware: |
Elizabeth Chamberlain / iFixit News: |
Lenny Rachitsky / Lenny's Newsletter: |
Jordan Novet / CNBC: |
Declan Harty / Politico: |
Dan Goodin / Ars Technica: |
Politico: |
Jessica Elgot / The Guardian: |
Lawrence Abrams / BleepingComputer: |
Andrew Silver / Reuters: |
Gian Volpicelli / Bloomberg: |
Reuters: |
Mark Chediak / Bloomberg: |
Loreben Tuquero / Poynter: |
This is a Techmeme archive page. It shows how the site appeared at 10:05 AM ET, November 11, 2026.
The most current version of the site as always is available at our home page. To view an earlier snapshot click here and then…
The cross-border startup is targeting the growing enterprise ecosystem by designing specialized analytics infrastructure tailored to autonomous digital software. This substantial launch capital allows the team to scale development across its dual headquarters in Israel and California. The move signals heightened investor appetite for back-end data architectures built expressly to serve next-generation artificial intelligence workflows.
Healthcare technology developers are increasingly pushing to ingest extensive patient records and administrative files to power broader clinical recommendations. This rapid transition from narrow, single-purpose functions to wide-ranging medical decision support challenges traditional clinical perspectives on data limitation. The shift marks an aggressive effort by digital health platforms to expand their operational footprints across patient care.
To accelerate therapeutic development, Anthropic has forged partnerships with pharmaceutical companies and biotechs like Bristol Myers Squibb and BigHat Biosciences. The initiatives leverage the company's Claude AI models to engineer treatments for rare diseases, food allergies, and various forms of cancer. While laboratory tests show promise in optimizing drug molecules, the technologies remain strictly in preclinical development phases.